ENDP, чудесная малышка: "Revenues came in at $772 million in the third quarter, surpassing the Zacks Consensus Estimate of $668 million. Revenues rose 22% from the year-ago quarter due to increased revenues from the Sterile Injectables, Generic Pharmaceuticals and Branded Pharmaceuticals segments." #МиллионыДомаСТинькофф